JP7843289B2 - アデノシン誘導体及びそれを含む医薬組成物 - Google Patents

アデノシン誘導体及びそれを含む医薬組成物

Info

Publication number
JP7843289B2
JP7843289B2 JP2023543239A JP2023543239A JP7843289B2 JP 7843289 B2 JP7843289 B2 JP 7843289B2 JP 2023543239 A JP2023543239 A JP 2023543239A JP 2023543239 A JP2023543239 A JP 2023543239A JP 7843289 B2 JP7843289 B2 JP 7843289B2
Authority
JP
Japan
Prior art keywords
alkyl
group
pharmaceutical composition
bond
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023543239A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503723A5 (cg-RX-API-DMAC7.html
JP2024503723A (ja
Inventor
スー,リャンホン
Original Assignee
ブリー バイオサイエンシーズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブリー バイオサイエンシーズ, インコーポレイテッド filed Critical ブリー バイオサイエンシーズ, インコーポレイテッド
Publication of JP2024503723A publication Critical patent/JP2024503723A/ja
Publication of JP2024503723A5 publication Critical patent/JP2024503723A5/ja
Application granted granted Critical
Publication of JP7843289B2 publication Critical patent/JP7843289B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023543239A 2021-01-25 2022-01-25 アデノシン誘導体及びそれを含む医薬組成物 Active JP7843289B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163141450P 2021-01-25 2021-01-25
US63/141,450 2021-01-25
PCT/US2022/013660 WO2022159872A1 (en) 2021-01-25 2022-01-25 Adenosine derivative and pharmaceutical composition comprising the same

Publications (3)

Publication Number Publication Date
JP2024503723A JP2024503723A (ja) 2024-01-26
JP2024503723A5 JP2024503723A5 (cg-RX-API-DMAC7.html) 2025-01-15
JP7843289B2 true JP7843289B2 (ja) 2026-04-09

Family

ID=82494279

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023543239A Active JP7843289B2 (ja) 2021-01-25 2022-01-25 アデノシン誘導体及びそれを含む医薬組成物

Country Status (11)

Country Link
US (2) US11793827B2 (cg-RX-API-DMAC7.html)
EP (1) EP4281081A4 (cg-RX-API-DMAC7.html)
JP (1) JP7843289B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230132476A (cg-RX-API-DMAC7.html)
CN (1) CN116710465A (cg-RX-API-DMAC7.html)
AU (1) AU2022210781A1 (cg-RX-API-DMAC7.html)
CA (1) CA3202049A1 (cg-RX-API-DMAC7.html)
IL (1) IL304366A (cg-RX-API-DMAC7.html)
MX (1) MX2023008004A (cg-RX-API-DMAC7.html)
WO (1) WO2022159872A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202408803B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL289925B2 (en) 2019-07-27 2026-03-01 Brii Biosciences Inc A derivative of adenosine and a pharmaceutical preparation containing it
AU2022211056A1 (en) 2021-01-25 2023-07-20 Brii Biosciences, Inc. Combination therapy for hiv with adenosine derivative and capsid inhibitors
KR20230132476A (ko) 2021-01-25 2023-09-15 브리 바이오사이언시스, 인크. 아데노신 유도체 및 이를 포함하는 약제학적 조성물
EP4658663A2 (en) * 2023-01-30 2025-12-10 Merck Sharp & Dohme LLC Prodrugs of 4'-substituted nucleoside reverse transcriptase inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017512797A (ja) 2014-03-28 2017-05-25 メルク・シャープ・アンド・ドーム・コーポレーションM Hiv逆転写酵素阻害剤としての4’置換ヌクレオシド誘導体
WO2019171285A1 (en) 2018-03-07 2019-09-12 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
WO2020031131A1 (en) 2018-08-09 2020-02-13 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
WO2020044257A1 (en) 2018-08-30 2020-03-05 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
WO2020178767A1 (en) 2019-03-06 2020-09-10 Glaxosmithkline Intellectual Property Development Limited Compounds useful in hiv therapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3407191A (en) * 1966-08-29 1968-10-22 Lilly Co Eli Adamantoate esters of nucleosides
US5880154A (en) 1994-02-01 1999-03-09 The Board Of Regents Of The University Of Nebraska Polymeric adamantane analogues
EP1667694B1 (en) 2003-09-05 2010-04-28 Anadys Pharmaceuticals, Inc. Tlr7 ligands for the treatment of hepatitis c
CA2502109C (en) 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
EP1915053A2 (en) 2005-08-12 2008-04-30 Merck & Co., Inc. Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives
EP2040712B1 (en) 2006-07-18 2011-03-02 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
WO2011058582A1 (en) 2009-11-16 2011-05-19 Orchid Research Laboratories Ltd. Histone deacetylase inhibitors for the treatment of fungal infections
WO2015187596A2 (en) 2014-06-02 2015-12-10 Regeneron Pharmaceuticals, Inc. Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses
JP6768796B2 (ja) * 2015-09-23 2020-10-14 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 4’−置換ヌクレオシド逆転写酵素阻害剤及びその調製
US20180030080A1 (en) * 2016-07-28 2018-02-01 Alexandre Vasilievich Ivachtchenko Phosphoramidate nucleoside prodrug for treating viral diseases and cancer, processes for their preparation and their use
US10266558B2 (en) * 2016-10-07 2019-04-23 Alexandre Vasilievich Ivachtchenko Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof
US11337964B2 (en) 2017-02-28 2022-05-24 Kangpu Biopharmaceuticals, Ltd. Isoindoline derivative, pharmaceutical composition and use thereof
RU2659388C1 (ru) * 2017-02-28 2018-07-02 Васильевич Иващенко Александр Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение
US20190185508A1 (en) * 2017-12-15 2019-06-20 Merck Sharp & Dohme Corp. Deuterated nucleoside reverse transcriptase inhibitors
CN109053803A (zh) 2018-07-04 2018-12-21 米文君 一类新的化合物及其用途
IL289925B2 (en) 2019-07-27 2026-03-01 Brii Biosciences Inc A derivative of adenosine and a pharmaceutical preparation containing it
WO2021038509A1 (en) 2019-08-28 2021-03-04 Glaxosmithkline Intellectual Property (No.2) Limited 4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy
MX2022002897A (es) 2019-09-11 2022-05-16 Scripps Research Inst Profarmacos antivirales y formulaciones de los mismos.
AU2022211056A1 (en) 2021-01-25 2023-07-20 Brii Biosciences, Inc. Combination therapy for hiv with adenosine derivative and capsid inhibitors
KR20230132476A (ko) * 2021-01-25 2023-09-15 브리 바이오사이언시스, 인크. 아데노신 유도체 및 이를 포함하는 약제학적 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017512797A (ja) 2014-03-28 2017-05-25 メルク・シャープ・アンド・ドーム・コーポレーションM Hiv逆転写酵素阻害剤としての4’置換ヌクレオシド誘導体
WO2019171285A1 (en) 2018-03-07 2019-09-12 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
WO2020031131A1 (en) 2018-08-09 2020-02-13 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
WO2020044257A1 (en) 2018-08-30 2020-03-05 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
WO2020178767A1 (en) 2019-03-06 2020-09-10 Glaxosmithkline Intellectual Property Development Limited Compounds useful in hiv therapy

Also Published As

Publication number Publication date
US12390484B2 (en) 2025-08-19
IL304366A (en) 2023-09-01
US20220233567A1 (en) 2022-07-28
EP4281081A1 (en) 2023-11-29
US11793827B2 (en) 2023-10-24
AU2022210781A1 (en) 2023-06-29
JP2024503723A (ja) 2024-01-26
AU2022210781A9 (en) 2024-10-10
WO2022159872A1 (en) 2022-07-28
KR20230132476A (ko) 2023-09-15
MX2023008004A (es) 2023-07-13
CA3202049A1 (en) 2022-07-28
TW202245805A (zh) 2022-12-01
CN116710465A (zh) 2023-09-05
EP4281081A4 (en) 2025-05-14
ZA202408803B (en) 2025-06-25
US20240245716A1 (en) 2024-07-25

Similar Documents

Publication Publication Date Title
JP7700096B2 (ja) アデノシン誘導体及びそれを含む薬学的組成物
US12390484B2 (en) Adenosine derivative and pharmaceutical composition comprising the same
JP6563585B2 (ja) 抗ウイルス性ベータ−アミノ酸エステルホスホジアミド化合物
JP6938637B2 (ja) テノホビルの抗ウイルス性脂肪族エステルプロドラッグ
CN110035760A (zh) 抗病毒苯甲基胺磷酰二胺化合物
JP2018531216A6 (ja) 抗ウイルス性ベータ−アミノ酸エステルホスホジアミド化合物
JP7799620B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
US20230399287A1 (en) Novel compounds
JP2021530474A (ja) 7−アミノ−5−チオ−チアゾロ[4,5−d]ピリミジンのリン酸塩およびホスホン酸塩誘導体ならびにcx3cr1および/またはcx3cl1のレベルの上昇に関連する治療条件におけるそれらの使用
EA051612B1 (ru) Производное аденозина и содержащая его фармацевтическая композиция
RU2824528C2 (ru) Аденозиновое производное и фармацевтическая композиция, содержащая его
EP3416970A1 (en) Cortistatin analogs
RU2851203C2 (ru) Тетрациклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич
US20210260082A1 (en) Phosphinic amide prodrugs of tenofovir
HK40074714A (en) Adenosine derivative and pharmaceutical composition comprising the same
HK40074714B (en) Adenosine derivative and pharmaceutical composition comprising the same
TW202517253A (zh) Cdk2抑制劑及其用途
TW202434594A (zh) 4'-經取代之核苷反轉錄酶抑制劑之前藥
TW202237146A (zh) 使用腺苷衍生物及衣殼抑制劑之hiv組合療法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250805

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260114

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260330

R150 Certificate of patent or registration of utility model

Ref document number: 7843289

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150